Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men.
Methamphetamine abusers often complain of feelings of depression that can complicate accurately diagnosing these individuals during treatments for methamphetamine abuse. This article presents an examination of temporal associations between documented methamphetamine use and reported ratings of depression among 162 gay and bisexual male methamphetamine abusers who participated in a 16-week randomized clinical trial of four behavioral therapies for methamphetamine abuse. Methamphetamine use was measured using thrice-weekly urine samples analyzed for drug metabolite. Self-reported depressive symptoms were collected weekly using the Beck Depression Inventory (BDI). At treatment entry, 73.2% of participants rated their depressive symptoms as mild or higher in severity (BDI>or=10), with 28.5% reporting BDI scores in the moderate to severe range (BDI>or=19). All participants reported significant decreases in depressive symptoms from baseline through the end of treatment, regardless of treatment condition, HIV status, or mood disorder diagnosis. A mixed regression model showed methamphetamine use for up to 5 days prior to the BDI score strongly predicted depressive symptoms (F1, 968=18.6, P<.0001), while BDI scores had no significant association with subsequent methamphetamine use. Findings show that behavioral methamphetamine abuse treatment yields reductions in methamphetamine use and concomitant depressive symptom ratings that are sustained to 1 year after treatment entry.
Peck
James A
JA
UCLA Integrated Substance Abuse Programs, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA. jpeck@mednet.ucla.edu
Reback
Cathy J
CJ
Yang
Xiaowei
X
Rotheram-Fuller
Erin
E
Shoptaw
Steven
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D019969:Amphetamine-Related Disorders / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D001521:Behavior Therapy; D001727:Bisexuality / Q000523:psychology*; D003863:Depression / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications; D018451:Homosexuality, Male / Q000523:psychology*; D006801:Humans; D008297:Male; D008694:Methamphetamine; D008875:Middle Aged; D012309:Risk-Taking; D012725:Sexual Behavior
D008694:Methamphetamine
West J Med. 1998 Feb;168(2):93-7
9499742
J Psychoactive Drugs. 2003 May;35 Suppl 1:161-8
12825759
Drug Alcohol Depend. 2005 May 9;78(2):125-34
15845315
J Psychoactive Drugs. 1998 Jul-Sep;30(3):239-45
9798789
Neurotox Res. 2002 Jun;4(4):297-313
12829420
J Consult Clin Psychol. 2003 Feb;71(1):53-61
12602425
J Subst Abuse Treat. 2002 Sep;23(2):145-50
12220612
J Addict Dis. 2002;21(1):107-19
11831496
Addiction. 2001 Nov;96(11):1589-601
11784456
J Subst Abuse Treat. 1995 Mar-Apr;12(2):117-27
7623389
Am J Psychiatry. 1993 May;150(5):763-9
8480823
J Stud Alcohol Suppl. 1994 Dec;12:70-5
7723001
J Subst Abuse Treat. 1996 Nov-Dec;13(6):493-7
9219147
J Neuropsychiatry Clin Neurosci. 2000 Fall;12(4):480-4
11083165
J Subst Abuse Treat. 1992;9(3):199-213
1334156